within Pharmacolibrary.Drugs.ATC.L;

model L04AG12
  extends Pharmacokinetic.Models.PK_1C_enteral(
    weight         = 70,
    F              = 0.64,
    Cl             = 0.005666666666666667,
    adminDuration  = 600,
    adminMass      = 0.02,
    adminCount     = 1,
    Vd             = 0.0058,
    Cmin           = 0.001,
    Cmax           = 0.01,
    Ctox_peak      = 0.02,
    Ctox_trough    = 0.01,
    ka             = 0.0,
    Tlag           = 0
  );

  annotation(Documentation(
    info ="<html><body><p>Ofatumumab is a fully human monoclonal antibody that specifically binds to the CD20 molecule present on the surface of B lymphocytes. It is used primarily for the treatment of chronic lymphocytic leukemia (CLL) and relapsing forms of multiple sclerosis (MS). Ofatumumab is approved and currently in clinical use for these indications.</p><h4>Pharmacokinetics</h4><p>Pharmacokinetic parameters are reported in adult patients with relapsing multiple sclerosis receiving subcutaneous ofatumumab.</p><h4>References</h4><ol><li><p>Bar-Or, A, et al., &amp; Fox, EJ (2022). Rapid and sustained B-cell depletion with subcutaneous ofatumumab in relapsing multiple sclerosis: APLIOS, a randomized phase-2 study. <i>Multiple sclerosis (Houndmills, Basingstoke, England)</i> 28(6) 910–924. DOI:<a href=&quot;https://doi.org/10.1177/13524585211044479&quot;>10.1177/13524585211044479</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/34605319/&quot;>https://pubmed.ncbi.nlm.nih.gov/34605319</a></p></li><li><p>Yu, H, et al., &amp; Soelberg Sørensen, P (2022). Population Pharmacokinetic-B Cell Modeling for Ofatumumab in Patients with Relapsing Multiple Sclerosis. <i>CNS drugs</i> 36(3) 283–300. DOI:<a href=&quot;https://doi.org/10.1007/s40263-021-00895-w&quot;>10.1007/s40263-021-00895-w</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/35233753/&quot;>https://pubmed.ncbi.nlm.nih.gov/35233753</a></p></li><li><p>Kurrasch, R, et al., &amp; Chang, DJ (2013). Subcutaneously administered ofatumumab in rheumatoid arthritis: a phase I/II study of safety, tolerability, pharmacokinetics, and pharmacodynamics. <i>The Journal of rheumatology</i> 40(7) 1089–1096. DOI:<a href=&quot;https://doi.org/10.3899/jrheum.121118&quot;>10.3899/jrheum.121118</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/23729801/&quot;>https://pubmed.ncbi.nlm.nih.gov/23729801</a></p></li></ol></body></html>",
    revisions = "<html><body><ul><li>06/2025 model generated by LLM gpt-4.1, references by scholarly and scripts created by Tomas Kulhanek</li></ul></body></html>"
  ));
end L04AG12;
